NCT03714152 - A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

November 23, 2020

Study Completion Date

January 7, 2021

Conditions

Chronic Hepatitis B

Interventions

DRUG

ABI-H2158

5 mg or 25 mg tablets

DRUG

Placebo for ABI-H2158

Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets

Trial Locations (14)

Research and Education, San Diego

Southern California Research Center, Coronado

Quest Clinical Research, San Francisco

First Hospital of Jilin University, Jilin

Infectious Disease Care, Hillsborough

Monash University, Clayton

The Alfred Hospital, Melbourne

Linear Clinical Research, Nedlands

University of Hong Kong, Queen Mary Hospital, Hong Kong

Auckland Clinical Studies, Auckland

Hallym University, Chuncheon

Asan Medical Center, Seoul

Severance Hospital, Yonsei University, Seoul

King's College London, London